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Abstract 
Psoriasis is a chronic systemic inflammatory skin disease of a complex etiology, 
involving genetic, immunological and environmental factors, in response to numerous 
triggers. The goal of this study is to summarize current available data on the importance 
of T-cells in conjunction with the innate immune system, involved in the 
immunopathogenesis of psoriasis.  
The genetics of psoriasis is complex and multifactorial. Genetic predisposition of 
the disease appears to play an important role in the susceptibility to develop psoriasis, 
with several different susceptibility loci (PSORS1–10) being identified, specifically HLA-
Cw6 within PSORS1 being identified as the major genetic determinant for psoriasis. 
Initially, psoriasis was considered solely to be due to the dysfunction of limiting 
keratinocyte proliferation. Infiltration of immune cells was noticed, but not considered to 
be key in the pathogenesis, and rather just a consequence of the hyper-proliferating 
keratinocytes. Involvement of the immune system in psoriasis is now widely accepted. 
Psoriatic skin lesions originate as a result of dysregulated interactions and amplification 
of innate and adaptive components of the immune system with resident cutaneous cell 
types. The major pathogenic pathway in psoriasis occurs when mature dermal dendritic 
cells (DCs) and inflammatory myeloid DCs produce cytokines such as interleukin (IL)-23 
and IL-12 to activate IL-17 producing T-cells, T-helper (Th) 1 cells, and Th22 cells. 
These cells are responsible for producing an abundance of psoriatic cytokines including 
IL-17, interferon-gamma, tumor necrosis factor-alpha, and IL-22. In response, epidermal 
keratinocytes upregulate messenger ribonucleic acid for a range of inflammatory 
products and produce chemokines and antimicrobial peptides, leading to an amplified 
and sustained psoriatic inflammation response. IL-23/Th17 is now recognized as the 
major axis of the psoriatic immune pathway. 
The understanding of the immunopathogenesis of psoriasis has resulted in several 
highly specific therapies. These therapies target specific components of the immune 
system, proving the importance of further research and the need of a comprehensive 
understanding of the immunopathogenesis of psoriasis, in order to significantly 
attenuate the patient’s signs and symptoms, and ultimately improve their quality of life.  
 
Keywords: Immunopathogenesis; Psoriasis; Keratinocytes; T-cells; Dendritic cells; 
Interleukin 23; Interleukin 17. 
 
 
 III 
Resumo 
A psoríase é uma doença dermatológica crónica, sistémica e inflamatória, de uma 
etiologia complexa, que envolve fatores genéticos, imunológicos e ambientais, em 
reposta a numerosos “triggers”. Esta revisão bibliográfica tem como objetivo resumir os 
diversos estudos disponíveis sobre a importância das células T, em conjunto com o 
sistema imune na imunopatogénese da psoríase. 
A genética da psoríase é complexa e multifactorial. A predisposição genética para a 
doença parece desempenhar um papel importante na suscetibilidade ao seu 
desenvolvimento, identificando-se diversos loci de suscetibilidade diferentes (PSORS1-
10), com particular relevância do HLA-Cw6 no PSORS1, identificado como o principal 
determinante genético da psoríase. 
Inicialmente, a psoríase foi considerada apenas como sendo devido à disfunção em 
limitar a proliferação dos queratinócitos. A presença de células do sistema imune foi 
observada, mas não considerada um mecanismo chave na patogénese, e sim apenas 
uma consequência desta hiperproliferação. O envolvimento do sistema imune na 
patogénese da psoríase é atualmente amplamente aceite. As lesões cutâneas da 
psoríase originam devido a interações desreguladas e amplificadas das células do 
sistema inato e adaptativo com as células cutâneas. A via patogénica principal na 
psoríase ocorre quando as células dendríticas (DCs) maduras da derme e as DCs 
mieloides inflamatórias produzem citocinas como a interleucina (IL-) 23 e IL-12, 
ativando as células T produtoras de IL-17, as células T-helper (Th) 1 e as células Th22. 
Estas células são responsáveis pela produção de um número abundante de citocinas 
psoriátricas, incluindo a IL-17, o interferão-gama, fator de necrose tumoral-alfa e a IL-
22. Em resposta a esta citoquinas, os queratinócitos da epiderme sobre-regulam a 
expressão de mensageiros do ácido ribonucleico para vários produtos inflamatórios e 
produzem quimiocinas e peptídeos antimicrobianos, levando à amplificação e 
sustentação da resposta inflamatória. A via IL-23/Th17 é atualmente reconhecida como 
a principal via na resposta imune da psoríase. 
A compreensão da imunopatogénese da psoríase resultou no desenvolvimento de 
vários fármacos específicos para o tratamento da doença. Este fármacos têm como 
alvo componentes específicos do sistema imune, comprovando a importância de futuros 
estudos nesta área e a necessidade de uma compreensão abrangente da 
imunopatogénese da psoríase, a fim de atenuar significativamente os sinais e sintomas 
dos doentes com psoríase e melhorar a sua qualidade de vida. 
 
Palavras chave: Imunopatogénese; Psoríase; Queratinócitos; Células T; Células 
Dendríticas; Interleucina 23; Interleucina 17. 
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Abbreviation List 
α – Alpha   
AMPs – Antimicrobial Peptides  
β – beta 
DCs – Dendritic Cells  
DNA - Deoxyribonucleic Acid  
EDC – Epidermal Differentiation 
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Transcription Factor 3 
γ – Gamma 
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LCs – Langerhans Cells  
LL37 – Cathelicidin  
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NF-κB – Nuclear Transcription Factor-
κB  
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NK – Natural Killer 
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Index 
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Th – T-helper  
TLR – Toll Like Receptor  
TNF – Tumor Necrosis Factor  
Treg – Regulatory T-cell 
Tyk2 – Tyrosine Kinase-2  
VEGF – Vascular Endothelial Growth 
Factor  
 
 
 
 
 2 
I. Introduction 
Psoriasis is a chronic systemic inflammatory skin disease that affects about 2-3% of 
the worldwide population [1].  
The exact mechanisms of psoriasis immunopathogenesis is not completely recognized 
[2]. There is considerable evidence indicating that psoriasis pathogenesis is a complex 
interaction between genetic, immunological, and environmental components [3]. Several 
environmental factors have been shown to trigger the first episode of psoriasis in individuals 
genetically predisposed [4]. These triggers include physical trauma (sunburn and surgery), 
psychological stress, infections (bacterial pharyngitis and human immunodeficiency virus 
type 1) and drugs (β-blockers, angiotensin-converting enzyme inhibitors, antimalarials 
cloroquine, tetracyclines, nonsteroidal anti-inflammatory drugs and lithium) [4-6]. Psoriasis is 
also associated with multiple co-morbidities including arthritis, inflammatory bowel disease, 
cardiovascular disease, obesity, hypertension, diabetes mellitus, and depression [7]. 
Plaque-type psoriasis is the most common form, affecting 80 to 90% of patients [8]. It 
typically presents as erythematous plaques covered with a silvery white scale, that can 
easily be removed, revealing focal bleeding points (the Auspitz sign) [9]. Lesions often begin 
as small papules that expand and coalesce to form extensive psoriatic plaques. These 
lesions are typically distributed symmetrically on the scalp, elbows, knees, and lumbosacral 
area [5]. Histologically, psoriasis lesions are characterized by acanthosis, loss of the 
granular layer, parakeratosis, hyperkeratosis, angiogenesis and a dense infiltration by 
immune cells, namely T-cells, dendritic cells (DCs) and macrophages [10, 11]. These 
immune effectors produce pro-inflammatory cytokines such as tumor necrosis factor-alpha 
(TNF-α), interferon-gamma (IFN-γ), IL-17, IL-22, IL-23 and IL-1 beta (β). Neutrophils collect 
in the epidermis and form collections called Munro’s microabscesses. Plaques are highly 
vascular and new vessel formation is mediated by angiogenic factors such as vascular 
endothelial growth factor (VEGF) [7]. 
Genetic and immunology research have converged to shape the current pathogenic 
model for psoriasis, highlighting the key roles of the innate and adaptive immune pathways 
[7]. Keratinocytes are key participants in innate immunity recruiting T-cells to the skin, and T-
cells are important in sustaining disease activity. Inflammatory myeloid DCs release IL-23 
and IL-12 to activate IL-17 producing T-cells (T cytotoxic cell 17 and Th17), Th1 cells, and 
Th22 cells to produce abundant psoriatic cytokines IL-17, IFN-γ, TNF-α, and IL-22. These 
cytokines mediate effects on keratinocytes to amplify psoriatic inflammation [12-14]. Several 
studies suggest that psoriasis is a Th17 cell-mediated disease controlled by IL-23. TNF-α 
also stimulates CD11+ inflammatory DCs to produce IL-23 and IL-20 and seems to be a 
critical cytokine for many of the pathogenetic features of psoriasis [3].  
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A search in the PubMed database (up until April 2017) for articles with the specific 
keywords: Immunopathogenesis, Psoriasis, Keratinocytes, T-cells, Dendritic cells, Interleukin 
23, and Interleukin 17, present in the title, abstract, or body was performed. The reference 
lists of those articles were examined to retrieve other studies that were considered relevant 
and contributive to the scientific purpose of the present review but had not been retrieved by 
the database search. Therefore, this article summarizes current knowledge regarding the 
immunopathogenesis of psoriasis. 
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II. Psoriasis 
The pathogenesis of psoriasis involves dynamic interactions between multiple cell 
types and numerous cytokines in response to triggers in genetically predisposed individuals, 
culminating in the disruption of skin immune homeostasis [7].   
Initially, psoriasis was considered to solely be due to a dysfunction of limiting 
keratinocyte proliferation. Infiltration of immune cells was noticed, but not considered to be 
relevant, and rather just a consequence of the hyper-proliferating keratinocytes [1]. The 
evidence that the immune system (T-lymphocytes and dendritic cells) played a more integral 
role in psoriasis has come with clinical and translational research involving human subjects, 
as administration of immune suppressive agents, such as Cyclosporine, Denileukin Diftitox, 
and Alefacept, proved successful in improving disease [1, 12]. 
Psoriasis pathogenesis includes hyper-proliferation and aberrant differentiation of 
keratinocytes, inflammation and dermal angiogenesis [9]. Histological features in psoriasis 
include proliferation and aberrant differentiation of epidermal keratinocytes, hyperkeratosis, 
infiltration of immune cells and subsequent typical thickening of the erythematous skin. The 
epidermis is greatly thickened (acanthosis), with elongation of the rete ridges that protrude 
down into the thickened papillary dermis. This epidermal thickening is due to a dramatic 
increase in the proliferation of psoriatic keratinocytes at the base of the epidermis. This leads 
to reduced maturation of the cells as they journey outward and retention of keratinocyte 
nuclei, which can be seen in the scaly layer (the stratum corneum) as parakeratosis. 
Collections of neutrophils can also be seen in the epidermis and stratum corneum. These 
histological features give rise to the characteristic clinical observation of a silvery scale 
shown by almost all psoriasis lesions. In the dermis, there is elongation and dilation of the 
dermal blood vessels that protrude up between the rete ridges, giving rise to the red color of 
psoriasis lesions. These dermal blood vessels and surrounding upper dermal spaces are 
filled with leukocytes, including DCs, neutrophils, macrophages, and mast cells, as well as T-
cells [3, 10]. 
Although the exact mechanisms for the induction of psoriasis are not yet fully 
elucidated, Gilliet and Lande have suggested a model of psoriasis initiation involving toll like 
receptors (TLRs), antimicrobial peptide LL37 (cathelicidin) released by keratinocytes, and 
plasmacytoid dendritic cells (pDCs) [15]. When triggering factors cause skin injury, 
keratinocytes produce LL37 in response, which then mediates the breakdown of tolerance to 
self-nucleic acids. LL37 binds with pathogen-derived deoxyribonucleic acid (DNA) or self-
DNA that has been released by stressed or dying cells and form DNA/LL37 complexes that 
bind to intracellular toll like receptor (TLR) 9 on pDCs. This promotes type I IFN-α and -β 
activation and release, which along with TNF-α, IL-6 and IL-1β, activates local myeloid DCs, 
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thus promoting T-cell mediated inflammation. LL37 may also bind to self-ribonucleic acid 
(RNA) and directly activate pDCs through TLR7 and myeloid DCs via TLR8 [7, 12, 16]. 
Myeloid DCs migrate into draining lymph nodes and release cytokines including TNF-
α, IL-23 and IL-12 that activate allogeneic T-cells. Once activated, T-cells enter the 
circulation and move towards inflamed skin through interactions with adhesion molecules (P-
selectin and E-selectin) on the endothelial cells of blood vessels. The effector molecules 
secreted by T-cells then activate keratinocytes, resulting in the release of cytokines and 
chemokines that continue to recruit and activate inflammatory cells. IFN-γ, IL-17 and IL-22 
are secreted by Th1, Th17 and Th22 cells, respectively, which contribute to the amplification 
of cutaneous inflammation [7]. IFN-γ promotes hyper-proliferation of keratinocytes by 
inhibiting apoptosis and increases intercellular adhesion molecule (ICAM) 1 expression in 
the endothelial cells, facilitating lymphocyte circulation. IL-17 interacts with IFN-γ, increasing 
the synthesis of pro-inflammatory cytokines by keratinocytes (IL-6 and IL-8), which increases 
the chemoattraction of T-cells into the skin, helping to maintain the psoriasis plaque [4]. 
The roles of different T-cell subsets in psoriasis, including Th1 (IFN-γ), Th17 (IL-17), 
and Th22 (IL-22), have been dissected through the testing of a range of cytokine 
antagonists. From this network of chemical mediators IL-23 and IL-17 look like the most 
interesting molecules to be investigated. The first specific indication that the immune system 
could be playing a more integral role came with the clinical trial targeting T-cells with a fusion 
protein also called Denileukin Diftitox, that causes apoptosis in activated T-cells expressing 
functional IL-2 receptors. In mice, a topical biologic response modifier Imiquimod (TLR7 
agonist) induces psoriasiform skin inflammation mediated by the IL-23/Th17 axis and 
activated DCs. Therefore, TLRs may trigger signal-transduction pathways that turn on 
expression of genes with important functions in psoriasis. The immune circuit described 
previously is amplified by the reaction of keratinocytes and myeloid DCs. In response to 
cytokines from each of the T-cell subsets, keratinocytes upregulate messenger RNAs for a 
range of inflammatory products, which feedback on immune cells in the skin so that chronic 
T-cell activation persists [4, 12, 16]. 
Recently IL-36 has driven the attention of several investigators with its role in triggering 
psoriasis and is a good candidate as a target molecule for new therapies in the future. IL-36 
is a key molecule for innate immunity dysfunction in psoriasis. Furthermore it is able to 
cross-talk with keratinocytes and dendritic cells producing TNF-α and has regulatory 
functions on IL-23/IL-17/IL-22, the main pathways investigated in psoriasis in the last years 
[4]. 
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III. Genetic Studies 
Several studies have demonstrated that genetic predisposition has an important role in 
the susceptibility to develop psoriasis. The likelihood of developing psoriasis is raised when 
first-grade relatives suffer from the disease. The risk is about 20% if one parent has 
psoriasis, and is about 75% if both parents are affected [11]. These studies also show that 
the concordance rate for dizygotic twins is only 22% compared with a high rate of 72% for 
monozygotic twins [4]. 
One of the earliest candidate genes for predisposition to psoriasis was the HLA class I 
allele, specifically HLA-Cw6 [6]. People with HLA-Cw6, for example, have a 10-fold higher 
risk of disease [11]. HLA class I and II antigens such as HLA-B13, -B17, -B39, -B57,  -Cw7, -
DR4 and -DR7 also have been shown to be positively associated with the pathogenesis of 
psoriasis [4]. Early onset psoriasis (before 40 years) has been reported to have a stronger 
genetic basis, because a greater proportion of patients had a family history of psoriasis, 
more severe disease, and stronger HLA associations [5].  
By using genome-wide scans (GWAS), investigators have mapped (with varying 
degrees of confidence) at least several different susceptibility loci, designated PSORS1–
PSORS10 [6]. Major susceptibility loci for psoriasis have been established at chromosome 
6p21.3 (PSOR1), whereas other associations have been reported on chromosomes 17q 
(PSORS2), 4q (PSORS3), 1cenq21 (PSORS4), 3q21 (PSORS5), 19p (PSORS6), 1p 
(PSORS7), and 4q31 (PSOR9) (Table 1) [5, 17]. The major genetic determinant for psoriasis 
is within the PSORS1 region of the MHC, as reported by several independent groups, 
accounting for 30–50% genetic susceptibility. The likely causal allele within PSORS1 is HLA-
Cw6, which encodes a class I major histocompatibility complex (MHC) molecule that is 
expressed by antigen presenting cells and mediates T cell activation. The second most well 
characterized disease-susceptibility locus (PSORS2) resides within 17q24–q25. Linkage of 
psoriasis to this locus has been identified by independent family sets [6, 7].  
Table 1: Psoriasis susceptibility loci (PSORS) 2–10 [17]. 
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Several psoriasis-associated genes belonging to the IL-23/Th17 axis, the nuclear 
transcription factor-κB (NF-κB) signaling pathway, and the epidermal differentiation complex 
(EDC) have been identified, which suggests that these pathways are critically involved in 
psoriasis pathogenesis [17]. 
Also genes expressed within keratinocytes that promote innate responses to viral 
nucleic acids and are upregulated in psoriatic skin lesions have been found by GWAS to 
confer disease susceptibility. The RIG-I and MDA5 innate antiviral receptors, encoded by the 
psoriasis-associated genes DDX58 and IFIH1, respectively, bind to viral double-stranded 
RNA and promote the release of pro-inflammatory cytokines that have been implicated in 
psoriatic lesion initiation such as type I IFN, IL-1, IL-6, and IL-29. Dysregulated antiviral 
immunity may contribute to the development of psoriasis by promoting the over-production of 
pro-inflammatory cytokines by keratinocytes [7]. 
 
 
IV. Innate Immunity 
1. Dendritic Cells 
DCs are professional antigen presenting cells that activate T-cells and are an 
important source of pro-inflammatory cytokines and chemokines in psoriasis. In the skin, the 
main DC populations include epidermal DCs (Langerhans cells) and dermal DCs (myeloid 
and plasmacytoid).  
Myeloid DCs (mDCs) express a distinct cell surface marker, CD11c, which is 
considered to be important in the early stages of disease. The blood DC antigens identify 
different subsets of myeloid DCs, such as BDCA-1+ “resident” DCs and BDCA-1- 
“inflammatory” DCs. Both these DCs can stimulate T-cells robustly in an allogeneic mixed 
lymphocyte reaction and similarly induce allogeneic T-cells to produce IFN-γ and IL-17 [7, 
12]. During psoriatic inflammation there is a 30-fold increase in CD11c+ mDCs in the dermis 
of psoriatic skin lesions compared with uninvolved psoriatic or normal skin (BDCA-1- 
“inflammatory” DCs, not the BDCA-1+ “resident” DCs). A large proportion of these DCs 
express TNF and the enzyme-inducible nitric oxide synthase (iNOS). TNF-α induces 
expression of ICAM-1 in keratinocytes, stimulates keratinocytes and dermal fibroblasts to 
produce IL-8, as well as pro-inflammatory cytokines (IL-6 and IL-1) that stimulate Th17. The 
important role of TNF-α will be explained in more detail in this article. iNOS is not usually 
found in normal resting cells but is induced in response to inflammatory stimuli. It is the 
enzyme responsible for the generation of nitric oxide (NO). In the skin, NO plays many roles, 
including vasodilation, inflammation, and an antimicrobial effect. Along with TNF-α and 
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iNOS, “inflammatory” DCs produce other pathogenic cytokines, such as IL- 20, which 
enhances keratinocyte activation and proliferation, and IL-23, which aids in differentiation, 
proliferation, and survival of Th17 cells (Figure 1) [10, 16]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The development and function of myeloid inflammatory DCs in psoriasis. As a result of 
cytokine production in the cutaneous microenvironment, DC precursors differentiate into inflammatory 
DCs in situ. Depending on the environmental cues, inflammatory DCs produce a distinct set of 
cytokines. Psoriatic DCs produce TNF-α, NO, IL-20, and IL-23 and are involved in the development 
and maintenance of a Th1/Th17 polarized response [10]. 
Plasmacytoid DCs are a rich source of type I IFN, an early signature cytokine in 
psoriasis. Type I IFNs comprise IFN-α and IFN-β, amongst others. In the case of psoriasis, 
tolerance to self-DNA can be broken, so self-DNA forms aggregates with LL37. LL37/DNA 
complexes prevent DNA degradation by nucleases and allow for endocytosis by pDCs to 
initiate disease. Sustained interactions of self-DNA with intracellular TLR9 induce production 
of large amounts of IFN-α. Type I IFN promotes myeloid DC phenotypic maturation and 
activation, thus facilitating T-cell priming. Type I IFN signaling modulates the production of 
IFN-γ and IL-17 and has been implicated in the differentiation and activation of T-cells, in 
particular Th1 and T17 cells [7, 10, 18].  
Langerhans cells (LCs) are a type of immature antigen-presenting cells that reside in 
the epidermis [12]. The main role of LCs is to take up and process antigens or cytokines and 
migrate to local skin-draining lymph nodes where they present to antigen-specific T-cells 
[16]. However, the role of LCs in psoriasis immunopathogenesis is still unclear [17]. 
Recently, attention has focused on the potential importance of LCs in uninvolved skin sites 
of patients with psoriasis and it has been demonstrated that LC migration is impaired in early 
onset psoriasis (before 40 years of age) [12]. Treatment with TNF-α inhibitors (Adalimumab, 
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Etanercept) and anti-p40 antibody (Ustekinumab) significantly restored epidermal LC 
migration in uninvolved skin. Therefore, the loss of LC motility may have an impact on the 
ability of these cells to sense the local antigenic microenvironment and regulate cutaneous 
immune responses [12]. LCs in human skin preferentially activate Th2 and Th22 cells, based 
on ex-vivo functional analyses [16]. In a series of elegant experiments co-culturing epidermal 
CD1a+ LCs and T-cells from healthy skin of the same donor, Seneschal et al. showed that 
LCs could induce a regulatory T-cell (Treg) phenotype (CD3+ CD4+ CD25hi Foxp3+) [19]. 
 
2. Keratinocytes  
Keratinocytes are believed to be crucial in both the early stages of disease 
pathogenesis and later amplification of chronic inflammatory circuits. They form the body’s 
first line of defense against exogenous physical, chemical and microbial insults. Genetic 
studies indicate a role for skin barrier dysfunction in psoriasis since deletion of LCE3B and 
LCE3C genes, encoding stratum corneum proteins involved in terminal differentiation of the 
epidermis, was found to be associated with psoriasis [7].  
Keratinocytes respond to different danger signals, and orchestrate innate and adaptive 
immune responses, releasing antimicrobial peptides (AMPs) such as LL37, β-defensins, 
S100 proteins, peptide-glycan recognition proteins, calcium-dependent lectins (C-type 
lectins), and iron-metabolizing proteins such as lipocalin 2. These molecules have direct 
antimicrobial activity and also help to modulate immune cells by promoting the upregulation 
of pro-inflammatory cytokines such as IL-6 and IL-10 and chemokines such as IL-8 (CXCL8) 
and CXCL10. Keratinocytes may release these neutrophil chemoattractants in response to 
T-cell-derived inflammatory cytokines to drive neutrophil migration into the epidermis (Figure 
2) [7, 12, 17, 20]. 
The most likely initiator of the keratinocytes activation cycle is IL-1. Both the α and β 
isoforms of IL-1 are stored unprocessed in the cytoplasm of the cells as pro-IL-1α and pro-
IL-1β. When pattern-recognition receptors and Nod-like receptors recognize their ligands, 
caspase-1 is activated within the keratinocytes [17]. Activation of caspase-1 possibly cleaves 
pro-IL-1α, pro-IL-1β, and pro-IL-18, which help to initiate the cutaneous inflammatory 
response to injury. IL-1β effects the production of TNF-α by local keratinocytes and 
upregulates leucocyte chemotactic proteins (selectins), which promote the skin infiltration 
and activation of T-cells. IL-18 and IL-1β are further involved in the differentiation of Th1 
cells and Th17 cells, respectively [14]. This sets up positive feedback loops as activated Th1 
and Th17 cells release IFN-γ, IL-22 and IL-17, which drives keratinocyte proliferation and 
activation, hence contributing to the formation of a cutaneous plaque [7]. IL-17 also induces 
CCL20 expression from keratinocytes, which plays a central chemotactic role for 
inflammatory T-cells and DCs, and may provide an autocrine loop to increase the influx of 
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Th17 cells themselves. IL-22 modulates a set of genes involved in keratinocyte mobility and 
terminal differentiation. IL-22 is responsible for disrupting normal keratinocyte differentiation 
in psoriasis, resulting in epidermal hyperplasia and hypogranulosis. Both IL-17 and IL-22 can 
induce keratinocyte expression of the antimicrobial S100A7 (psoriasin), which in turn 
mediates further leucocyte chemotaxis. IFN-γ induces keratinocyte expression of CXCL9, 
CXCL10 and CXCL11 that contribute to the trafficking of CD8+ T-cells, into the psoriatic 
lesion [7, 17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Schema for the initiation of a psoriatic skin lesion. Triggers such as trauma and infections 
lead to the release of self-DNA and self-RNA, which form complexes with LL37 and activate pDCs 
and mDCs, respectively. pDCs secrete type I IFN and other cytokines including TNF-α, IL-6 and IL-
1β, which promote the activation of mDCs. These antigen presenting cells release pro-inflammatory 
cytokines that drive T-cell mediated inflammation and keratinocyte activation and proliferation. This 
promotes the recruitment and activation of further inflammatory cells such as neutrophils and 
macrophages, contributing to the formation of an inflamed cutaneous plaque. AMPs antimicrobial 
peptides [7]. 
Keratinocytes also produce cytokines and angiogenic factors, such as VEGF during 
inflammatory states, which induces angiogenesis by promoting the migration, survival and 
proliferation of endothelial cells, resulting in the formation of an erythematous and vascular 
plaque [7, 17]. 
 
3. Macrophages 
The role of macrophages in psoriasis is not yet fully characterized, but they probably 
contribute to the pathogenic inflammation in psoriasis by releasing key inflammatory 
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cytokines. Macrophages are present in psoriatic lesions and, via production of TNF, are 
thought to take part in the development of skin inflammation in psoriasis [7, 12, 17]. 
Macrophages show a three-fold increase in cell numbers in psoriatic lesional skin, with 
evidence of normalization after successful treatment. Cutaneous macrophages can be 
identified by their expression of CD163 (a myeloid cell hemoglobin/haptoglobin scavenger 
receptor), and activated macrophages produce high levels of TNF-α and are likely to 
regulate angiogenesis via the release of VEGF [7, 16]. 
Although, they have long been recognized as antigen-presenting cells, capable of 
activating memory T-cells during stimulation of the adaptive arm of the immune response, 
contrary to dendritic cells, they are unable to polarize allogeneic T-cells to produce IL-17 in 
psoriasis [12, 21]. 
 
4. Neutrophils  
Neutrophils are important in the early stages of psoriasis as they are involved in the 
recruitment and activation of T-cells and the proliferation and differentiation of keratinocytes 
[7]. Neutrophils are reportedly attracted to the skin by a number of chemotactic factors, 
including IL8/CXCL8, CXCL1, CXCL2, and IL-18. Keratinocytes produce chemokines in 
response to IL-17, and the receptors for these chemokines are on skin-infiltrating 
neutrophils. Neutrophils within the epidermis and stratum corneum (Kogoj and Munro’s 
microabscesses, respectively) produce reactive oxygen intermediates and proteolytic 
enzymes thought to promote local tissue destruction, unmask hidden antigens, or affect 
growth and differentiation of keratinocytes [20]. Elastase is a protease that is released by 
neutrophils in response to TNF-α or IL-8. It has several downstream effects, including the 
induction of keratinocyte proliferation and cleavage of cytokines into their active forms [7]. 
 
5. Mast Cells 
Mast cells are said to be involved in the pathogenesis of psoriasis [22]. Activated 
keratinocytes attract immune effector cells including mast cells, which further contribute to 
the pro-inflammatory environment producing cytokines and chemokines [9]. Mast cells 
secrete large amounts of TNF-α, IFN-γ, IL-8, and other mediators such as VEGF, to recruit 
neutrophils and lymphocytes during innate and T-cell mediated inflammation [5, 22]. 
Mast cells, particularly a subset containing tryptase and chymase, are enriched in the 
papillary dermis of psoriasis lesions [23].  Notably, mast cells staining positive for IL-17 were 
identified at higher densities than IL-17+ T-cells in psoriatic lesions [24]. In several human 
autoimmune and neurodegenerative diseases, including psoriasis, it has been shown that 
mast cells also produce several members of the IL-17 family (IL-17E which can influence 
Th2 type responses and IL-17A) [8, 9, 25, 26]. Mast cells frequently degranulate in early 
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eruptive and recurring psoriasis lesions and have been described as “ghost cells”. Increased 
mast cells and neutrophils release IL-17 into the skin though process of extracellular trap 
formation, conventional degranulation, and through the mechanistic stimulus of IL-23 and IL-
1β [23].   
 
6. Natural Killer Cells 
Natural killer (NK) T-cells are a heterogenous subset of T-cells that share features of 
both T-cells and NK cells [9]. Classically, NK T-cells are divided into three subsets: type I, or 
invariant NK (iNK) T, type II NK T and NK T-like cells [27]. In psoriatic lesions, the amount of 
NK T-cells is also increased in comparison with normal skin [11]. Although the exact role of 
NK and NK T-cells in psoriasis have not been thoroughly explored, it has been suggested 
that these innate immune cells may play a role in psoriasis by releasing several inflammatory 
cytokines, such as IFN-γ, TNF-α, and IL-22 [1, 12]. However, the function of NK and NK T-
cells has not yet been fully understood, and further studies are required to evaluate their 
contribution to psoriasis [12, 16]. 
 
 
V. Adaptive Immunity 
A pivotal study demonstrated that inhibition of lymphocyte, but not keratinocyte, 
proliferation improved symptoms in patients with psoriasis, suggesting that psoriasis is a 
complex immune-mediated inflammatory disease driven primarily by T-cells [5, 24]. This 
conclusion concurred with immunohistochemical staining of psoriatic lesions showing CD3+ 
T-cells surrounding capillaries and CD4+ and CD8+ T-cells predominating in the dermis and 
epidermis, respectively [24]. This is supported by the effectiveness of several T-cell directed 
therapies in causing disease resolution. The first successful drug was DAB389IL-2, an IL-2 
fusion protein that causes apoptosis of activated T-cells expressing functional IL-2 receptors. 
The observed beneficial effects of other agents such as Abatacept (CTLA-4-Ig), which 
blocks T-cell co-stimulation, Alefacept an LFA-3-Ig fusion protein that inhibits effector 
memory T-cell activation, and Cyclosporine A (a substance that diminishes T-cell 
proliferation and cytokine production), further re-enforced the important pathogenic activity of 
this cell type in psoriasis [2, 5, 7, 24]. 
The importance of abnormal T-cell activation in the pathogenesis of psoriasis has been 
highlighted by several genetic studies that demonstrate a strong disease association 
between certain major histocompatibility complex class I alleles (such as HLA-Cw6, HLA-
B17, and HLA-Bw57) and psoriasis [2, 7].  
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T-cells can be subdivided into two classes: CD8+ cytotoxic T-cells and CD4+ helper T-
cells, both which are found to be increased in psoriasis [1]. Several CD4+ T-cells discretely 
produce IFN-γ, IL-17, and IL-22, with initial labeling of these cells as Th1, Th17, and Th22, 
respectively. There are also CD8+ T-cell populations, in the presence of IL-7 and IL-15 that 
make the same range of cytokines, so these have been termed T cytotoxic cells (Tc) 1, 17, 
and 22, respectively [2, 12].  
The presentation of cutaneous antigens by DCs in the skin stimulates the proliferation 
of antigen-recognizing T-cells and memory effector cells (Figure 3) [17, 22]. After antigen 
stimulation, T-cells enter the circulatory system and interact with adhesion molecules (P-
selectin and E-selectin) in endothelial cells of blood vessels [5, 11]. This interaction with 
adhesion molecules allows the migration and accumulation of T-cells, as well as 
macrophages, DCs, NK cells, and neutrophils through the blood vessel wall into the skin and 
around dermal blood vessels [5]. It has been postulated that an initial dermal helper T-cell 
(CD4+) infiltrate and trigger sequences of events that is obligatory for CD8+ T-cells to 
present their effector function [2]. The lymphocytic infiltrate and resident T-cells play 
important roles in preceding and stimulating hyper-proliferation and disrupt the differentiation 
process by interacting with keratinocytes. Expression of activation and memory markers on 
CD4+ and CD8+ lymphocytes point to the importance of these cells in the pathophysiology 
of psoriasis [2, 22]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Dendritic cells provide antigen presentation, co-stimulatory signals and cytokines to induce 
differentiation of naive T-cells into effector subsets. Th1 cells differentiate in the presence of IL-12 and 
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IFN-γ and produce IFN-γ and IL-18. These cytokines, in turn, facilitate macrophage-mediated 
immunity against intracellular bacteria, protozoa, and viruses. Th2 cells develop in the presence of IL-
4 and release IL-4, IL-5, IL-13, and IL-25. Th2 cells are important for cellular immunity against 
parasites and helminths mediated by basophils, eosinophils, and mast cells, as well as components of 
humoral immunity. Th17 cells require a combination of transforming growth factor (TGF)-β and pro-
inflammatory cytokines (IL-1β, IL-6, IL-21, and IL-23) to differentiate. They produce IL-17A, IL-17F, 
and IL-22 and are important in neutrophil-mediated protection against extracellular bacteria and fungi 
as well as in keratinocyte production of AMPs. Recently identified Th22 cells differentiate from naive 
T-cells in the presence of TNF and IL-6 and produce IL-22. IL-22 acts on epithelial cells, for instance, 
keratinocytes, which proliferate and increase their production of AMPs [17]. 
 
1. Interferon-gamma/T helper 1 
Naive CD4+ T-cells differentiate into Th1 cells in the presence of IL-12, and produce 
mainly IFN-γ, IL-2, and lymphotoxin. Cytokines produced by these cells activate 
macrophages and participate in the generation of T cytotoxic cells, leading to a cell-mediated 
anti-viral immune response. Th2 cells develop in the presence of IL-4, and produce IL-4, IL-
5, and IL-13, that mediate humoral immunity [2, 7].  
Evidence suggests that a shift in the balance between the Th1 and Th2 immune 
responses may play a role in promoting autoimmune reactions and immune dysfunction [2]. 
Psoriasis has traditionally been classified as a Th1 disease because of a predominance of 
Th1 pathway cytokines, such as TNF-α, IFN-γ, IL-2, and IL-12 in peripheral blood and 
psoriatic plaques of patients [4, 5, 9].  The data also suggest that IFN-γ in the serum of 
psoriatic patients was much higher than that of the control group, and correlated with the 
disease severity expressed as psoriasis activity and severity index (PASI) score, whereas 
Th2 cytokine (IL-4 and IL-10) levels were found to be lower. Since then, it has been widely 
recognized that the interaction of T-cells and DCs creates a ‘type 1’ inflammatory 
environment by secreting large amounts of Th1 type cytokines, leading to the development 
of psoriasis [9]. The exact mechanism responsible for Th1/Th2 polarization is not clear. 
There is increasing evidence to indicate that two transcription factors, T-bet and GATA-3, 
are the determining factors for Th1 and Th2 cell differentiation, respectively [2].  
Dendritic cells can instruct T-cells during priming to adopt a Th1 fate through secretion 
of the cytokine IL-12. IL-12 is composed of two subunits, p35 and p40. It was found that p40 
expression is increased in psoriasis [1]. When the Th1 differentiation pathway is activated, 
IFN-γ and TNF-α are produced [24].  
Activated Th1 cells are defined by their expression of IFN-γ and IL-18, in addition to 
TNF and IL-1 [17]. IFN-γ is a type II IFN, also secreted by DCs and NK cells. It is postulated 
that IFN-γ is more relevant in the early stages of disease, accelerating the migration of 
immune cells into the skin and activating antigen presenting cells (monocytes, macrophages, 
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DCs, and endothelial cell) [5, 7]. It also stimulates chemokines (CXCL10 and CXCL11), 
adhesion molecule release from keratinocytes, epidermal cell proliferation and inhibits the 
apoptosis of keratinocytes, causing the hyper-proliferation of keratinocytes observed in 
psoriatic plaques [22]. IL-12 secreted by DCs, together with IL-2 from T-cells, regulate the 
transcription of IFN-γ and TNF-α [5]. However, the dominant role of IFN-γ in psoriasis is now 
less clear after the discovery of IL-17 [28]. Most likely the IL-12/IFN-γ axis does not 
participate directly in maintaining chronic skin disease in psoriasis, because selective 
blockade of IL-23 leads to full resolution of psoriasis based on clinical, histologic, and 
molecular disease markers. In the clinical trial of IL-23 specific monoclonal antibody, high 
levels of IL-12 and IFN-γ mRNA were maintained, whereas IL-17 levels were dramatically 
reduced in patients with psoriasis. Direct blockade of IFN-γ with a neutralizing antibody in 
patients with psoriasis was shown to have little or no therapeutic benefit, suggesting this 
cytokine does not directly drive the psoriasis phenotype in chronic lesions [12]. 
 
2. Tumor Necrosis Factor  
TNF-α is an important cytokine of the Th1 pathway [5]. TNF-α is produced by several 
different cells types in the context of cutaneous inflammation, including macrophages, 
keratinocytes, Th1 cells, Th17 cells, Th22 cells and BDCA-1 inflammatory DCs [7]. TNF-α 
regulates the ability of DCs to activate T-cells and stimulates the proliferation of cytokines, 
and adhesion molecules. It induces the expression of C-reactive protein, a key protein in the 
acute phase response, and IL-6. IL-6 mediates T-cell activation, stimulates keratinocyte 
hyper-proliferation and mediates the acute-phase response [5, 7, 22]. TNF-α also increases 
expression of CCL20, a chemokine that recruits mDCs and Th17 cells, and IL-8, a cytokine 
that provides a strong chemotactic signal for the recruitment of neutrophils. TNF-α promotes 
the infiltration of inflammatory cells such as T-cells and monocytes into the skin, through the 
upregulation of ICAM-1 [7]. TNF-α is an activator of IL-23 synthesis in DCs and enhances 
the effects of other cytokines relevant to psoriasis pathogenesis such as IL-17 [7, 12]. 
Therefore, the clinical benefit seen with TNF-α inhibitor biologics as therapy (Infliximab, 
Adalimumab and Etanercept) is linked to suppression of the IL-23/Th17 axis [3, 12, 24]. 
Although TNF-α blockade is very effective therapeutically, the diverse actions of the cytokine 
have resulted in numerous drug-associated side effects [7].  
 
3. Interleukin 23/T helper 17  
Evidence is accumulating to suggest that IL-23 and its resulting Th17 pathway play a 
more important role in psoriasis than IL-12 [29]. IL-23 and IL-12 share the common p40 
subunit, however IL-23 is produced by the combination of p40 with the p19 subunit, whereas 
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IL-12 is composed of p40 and p35 subunits [10, 18]. In psoriasis lesions, IL-23 is produced 
by BDCA-1 “inflammatory” DCs, BDCA-1+ “resident” DCs and macrophages, that mediate 
the terminal differentiation and activation of Th17 cells (including induction of IL-17A and 
IFN-γ), activation of keratinocytes and upregulation of TNF-α expression in macrophages, 
which in turn, drives and sustains the psoriatic disease process [4, 7, 12, 18].  
The IL-23 receptor (R) is a heterodimeric receptor, composed of IL-12RB1 and IL-23R. 
These receptor components lack intrinsic signaling activity, and signal through the 
interactions with downstream molecules [1]. IL-12B1 requires tyrosine kinase-2 (Tyk2) for 
signaling, whereas IL-23R requires janus kinase-2 (Jak2) [1, 4]. When Jak2 and Tyk2 are 
activated, this leads to the phosphorylation of the receptor complex and consequently to the 
activation of the transcription factors signal transducer and activator of transcription (STAT) 
3 and 4 which up regulate IFN-γ and allow Th17 differentiation, with its downstream 
secretion of IL-17A and other Th17 products [4]. 
In the case of psoriasis, the hypothesis that IL-12 was a driver of disease was based, 
in part, on detection of the p40 subunit in psoriatic lesions, which could have represented IL-
23 [24]. Results of numerous studies have indicated that levels of p19 and p40 mRNA, but 
not p35 mRNA, are substantially increased in psoriatic lesional skin compared with psoriatic 
non-lesional skin [18]. GWAS studies that link single nucleotide polymorphisms in/near IL-
23R, IL-23A, IL-12B, TYK2 and STAT3 with psoriasis susceptibility have highlighted IL-23 as 
a critical cytokine in disease pathogenesis [1, 7]. 
The importance of IL-23 in psoriasis pathogenesis has been further confirmed by the 
clinical improvements in patients through targeting this cytokine in the treatment of psoriasis 
[1, 18]. Monoclonal antibody treatment targeting especially the IL-23 specific p19 subunit 
have demonstrated outstanding clinical efficacy [1]. The most advanced of these agents are 
Tildrakizumab (humanized Ig-G1k monoclonal anti-IL-23p19 antibody that does not bind to 
IL-12 or p40) and Guselkumab (human IgG1 monoclonal anti-IL-23 antibody), both of which 
have shown promising results in phase 2 trials. BI 655066 is a human IgG1 monoclonal anti-
IL-23A antibody that is ongoing phase 2 studies in patients with moderate-to-severe chronic 
plaque psoriasis [18].  
Th 17 cells are CD4+ effector Th cells that are distinct from the classic Th1 and Th2 
lineages. Th17 cells differentiate from naive T-cells after stimulation by TGF-β, IL-6, IL-21, 
and IL-1β [30]. Th17 cells also activated by the combination of IL-23 and IL-1α or IL-1β, to 
produce multiple inflammatory cytokines [2, 4]. Th17 cells generate various cytokines such 
as IL-17A, IL-17F, IL-21, IL-22, IL-26, TNF-α and the chemokine CCL20, that play essential 
roles in a variety of chronic inflammatory diseases, including psoriasis [4, 9, 31].  
Evidence is now emerging that IL-17 is a key cytokine in the immunopathogenesis of 
psoriasis at the keratinocyte level [18]. The Th1 hypothesis of psoriasis pathogenesis was 
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revised after recognition that Th17 cells are a key T-cell population in lesional skin [24]. IL-17 
consists of a family of six members (IL-17A-F), with the role of IL-17A in psoriasis being the 
most extensively researched [7, 18]. Levels of IL-17A, IL-17F and IL-17C are significantly 
increased in psoriatic patients compared to healthy subjects [2, 4, 30]. IL-17C has recently 
been demonstrated to act on keratinocytes to induce pro-inflammatory cytokines, 
chemokines and AMPs, and this activity requires both IL-17 receptor (IL-17R) E and A [32]. 
Gene set enrichment analysis of the psoriasis transcriptome also reveals enrichment for IL-
17A genes [2, 12]. More recently, IL-17A or the IL-17R A subunit blocking agents have been 
shown to have rapid and high efficacy in clinical trials, showing a reverse in clinical, 
histologic, and molecular features of psoriasis in approximately 80% of patients with 
psoriasis given higher levels of the antagonists [7, 12]. Secukinumab, a monoclonal antibody 
that targets IL-17A, has been approved for the treatment of moderate-to-severe psoriasis 
[18]. A monoclonal antibody that inhibits IL-17A (Ixelkizumab) and monoclonal antibody that 
blocks the IL-17R (Broadalumab) are being researched for the treatment of psoriasis [26]. 
RG7624, an antibody that targets both IL-17A and IL-17F, is also being investigated for the 
treatment of psoriasis but no clinical trial results have been reported for this agent [25]. 
IL-17A acts on a variety of cell types including endothelial cells, fibroblasts, 
chondrocytes, synovial cells, monocytes, macrophages, dendritic cells, neutrophils, 
lymphocytes and epithelial cells including keratinocytes [2, 4, 30]. Keratinocytes are the 
predominant cells that express IL-17R in psoriasis [7]. There are a number of genes 
associated with psoriasis that may function downstream of the IL-17R signaling, such as 
TRAF3IP2 that codes for the Act-1 protein (also known as TRAF3-interacting protein 2), an 
intracellular protein that directly binds the IL-17R complex [33]. Act-1 can initiate two 
different signal transduction pathways in response to IL-17R activation: NF-κB signaling and 
stabilization of mRNAs induced by TNF [30]. NF-kB signaling events can be initiated through 
interactions with TRAF6, which induces expression of neutrophils, T-cells, and DC 
chemokines that lead to the migration of neutrophils, memory T-cells, and DCs to psoriatic 
lesions [4, 7, 18]. In the TRAF6-independent pathway, Act-1 can bind to TRAF5 and 
sequester the RNA binding factor SF2, leading to stabilization of inflammatory mRNAs [34]. 
Keratinocytes in turn are stimulated by IL-17A to produce AMPs, pro-inflammatory cytokines 
such as IL-19 (driving epidermal hyperplasia), IL-1, IL-6, and IL-23 and chemokines such as 
IL-8 (recruitment of neutrophils, T-cells and NK cells) [7, 24]. Neutrophils are attracted to the 
epidermis of psoriatic lesions by chemokines released from IL-17A-stimulated keratinocytes 
(CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL8), affecting the growth and 
differentiation of keratinocytes [4, 18]. IL-17A also increases production of the chemokine 
CCL20 and ICAM-1, which facilitate cutaneous recruitment of DCs and T-cells [7]. IL-17A 
increases the expression of antimicrobial peptides, including members of the β-defensin and 
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S100A families, thus stimulating the innate immune system. IL-17A has other effects on 
keratinocytes that can contribute to epidermal hyper-proliferation and skin barrier disruption: 
it increases expression of keratin, reduces expression of filaggrin, and alters expression of 
multiple genes involved in cell adhesion [24]. Moreover, DCs and keratinocytes in the skin 
lesions of psoriasis produce increased amounts of IL-23, a cytokine that promotes the 
development and proliferation of Th17 cells [2]. This process is illustrated in Figure 4 [30]. 
 
 
 
 
 
 
 
Figure 4: A model for the central role of IL-17 in psoriasis pathogenesis. This model includes core 
inflammatory elements that establish a self-reinforcing cycle, including Th17 skewing of naive T cells 
in the presence of IL-23 leading to the local production of IL-17 ligands. Keratinocytes in turn are 
stimulated by these IL-17 ligands, leading to an aberrant differentiation program and elevated 
production of pro-inflammatory factors including antimicrobial peptides and chemokines (including 
CCL20, which attracts both Th17 cells and DCs). These keratinocyte-derived factors in turn stimulate 
further recruitment of inflammatory cells, including IL-17–producing cells, and establish a self-
sustaining inflammatory feedback loop. CXCLs, CXC ligands, Tc and TNF [30]. 
IL-17A and other Th17 effector cytokines lead to further keratinocyte activation and 
inflammatory mediator production, thereby creating positive feedback loops such that 
epidermal hyperplasia and the cutaneous inflammatory response are sustained and 
amplified in the psoriatic lesion [7, 24]. IL-17 has recently been shown to act in synergy with 
TNF-α to induce pro-inflammatory cytokine production by keratinocytes and is therefore 
considered the most important pathogenic stimulant of keratinocytes in psoriasis [7, 12]. 
 
4. Interleukin 22/T helper 22 
IL-22 is a member of the IL-10 family of cytokines (along with IL-10, IL-19, IL-20, IL-24, 
and IL-26) and has been found to be upregulated in the skin and sera of patients with 
psoriasis [7, 35]. The production of IL-22 by Th22 cells and Th17 cells is induced by IL-23, 
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and has profound effects on epidermal keratinocytes, inducing hyperplasia, migration, and 
curtailing the normal differentiation pathway as well as the induction of a broad range of 
cytokines, chemokines, and acute-phase proteins from various inflammatory cells [5, 7, 35]. 
IL-22 has long been suspected of having a crucial role in the development of psoriasis skin 
lesions. This cytokine, along with the other IL-20 subfamily members, is upregulated in 
lesional psoriasis epidermis as well as in the blood of psoriasis patients and is restored to 
normal levels during effective treatment [35, 36].   
IL- 22 has been shown to act in synergy with IL-17A to induce AMP production by 
keratinocytes [9]. Blockade of IL-22 in vivo or genetic deletion caused reduced IL-23-induced 
epidermal hyperplasia, and IL-23-mediated epidermal hyperplasia in a murine model of 
psoriasiform skin inflammation was found to be dependent on IL-22. These data highlight 
potential crosstalk between the IL-23/Th17 pathway and IL-22/Th22 [7]. IL-22 has somewhat 
defied the paradigm of classification into the strict Th1, Th2, and Th17 categories, with IL-22 
secretion reported from Th1, Th17, and Tc22 cells as well as the more recently appreciated 
Th22 cells that produce IL-22 in the absence of IFN-γ, IL-4, or IL-17 [35]. In addition, several 
phenotypes of innate immune cells have been reported to produce IL-22, including NK cells, 
γδ T-cells, lymphoid tissue inducer cells, and type 3 innate lymphoid cells (ILC3). As such 
Th17, Th22, Tc22, ILC3, and NK cells have all been reported to be increased in number in 
psoriasis plaques [37]. The profound effects of IL-22 on skin are further heightened by 
powerful synergies with IL-17 and TNF, greatly amplifying its effects as well as those of IL-17 
and TNF on the cytokine network in psoriasis [35]. However, in contrast to the IL-23/Th17 
pathway, there is a lack of genetic data in support of a role for IL-22 in disease pathogenesis 
[7]. 
 
5. γδ T-cells 
Unlike dendritic epidermal γδ T-cells and conventional αβ T-cells, dermal γδ T-cells 
constitutively express IL-23 receptor, CCR6 and the transcriptional factor RORγt. More 
importantly, these cells are demonstrated to be the major IL-17 producer in the skin upon IL-
23 stimulation [9, 16]. In spite of their essential role in the normal host defense, γδ T-cells 
may also be involved in the pathogenesis of various skin diseases such as psoriasis [2]. 
Various authors have identified high numbers of γδ T-cells producing IL-17 in psoriatic skin 
lesions and suggesting a reciprocal relationship between IL-23 and γδ T-cells in the 
pathogenesis of psoriasis [38]. γδ T-cells in peripheral blood have been characterized as 
Vγ9Vδ2 (skin homing T-cell), CLA+ and CCR6+, and were able to produce IL-17A and 
activate keratinocytes via TNF and IFN-γ [12]. Psoriatic skin lesions have greatly increased 
numbers of γδ T-cells compared with healthy controls, and an IL-17 producing γδ T-cell 
population has been identified in the dermis [39]. Consequently, γδ T-cells may act in an 
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amplification loop for IL-17 synthesis and provide an alternative mechanism that may 
mediate autoimmune inflammation [2, 9].  
 
6. Regulatory T-cells 
Tregs are a subset of T lymphocytes that suppress not only autoimmune responses 
but also other aberrant or excessive immune responses to non-self-antigens [9]. Tregs use 
diverse pathways to maintain immune tolerance, including release of inhibitory cytokines, 
induction of apoptosis, and inhibition of IL-2 secretion. Some naturally occurring circulating 
Tregs can be identified as CD41, CD25high (IL-2R), forkhead/winged helix transcription factor 
3 (Foxp3+), and CD127 (IL-7R-) [12, 16]. 
When effector T-cells are not being sustained by Tregs, unstrained effector T-cell 
effects lead to autoimmunity [40]. Some studies have shown Tregs to be dysfunctional in 
psoriasis, with decreased suppressive capacity, suggesting that psoriasis may result from 
the inability to suppress auto-inflammation [12]. In fact, regulatory CD4+ T-cells from 
peripheral blood from patients with psoriasis have been shown to be deficient in their 
suppressor activity. Moreover, in psoriatic plaques, psoriatic regulatory T-cell population 
demonstrated decreased suppression of effector T-cells [11]. However, further studies are 
needed to evaluate Tregs contribution in psoriasis, as function of skin-derived Tregs has not 
yet been well examined [12]. 
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VI. Conclusion 
Molecular and cellular understanding of psoriasis pathogenesis has evolved 
considerably in the last decade. The precise knowledge of the immunological mechanisms of 
psoriasis, characterizing the role of each cytokine involved in psoriasis inflammation, made it 
possible to recognize it as a systemic disease. Psoriasis was initially thought to be a skin 
disease driven by keratinocyte hyper-proliferation, but the role of the immune system and T-
cells in psoriasis pathogenesis has been largely recognized.  
The presence of the IL-12 cytokine in psoriatic lesions led researches to postulate that 
psoriasis was mediated by Th1 cells. Instead of the traditional view regarding psoriasis as a 
Th1 type disease, it is clearer that collectively, Th1, Th17, Treg, Th22, IFN-γ and TNF-α can 
cause keratinocyte proliferation and cytokine, chemokine, and antimicrobial peptide 
production. This becomes a self-amplifying loop, where these products act back on the DCs, 
T-cells, and neutrophils to perpetuate the cutaneous inflammatory process. Additionally, IL-
17A, the principal effector cytokine of Th17 cells, stimulates keratinocytes to produce 
chemokines, cytokines, and other pro-inflammatory mediators thereby enabling IL-17A to 
bridge the innate and adaptive immune systems to sustain chronic inflammation. 
Clinical and translational research in human subjects has enabled a better 
understanding of the immunology of psoriasis, and subsequently the development of novel 
immune-targeted therapeutics. Selected target therapy starting from anti TNF-α, together 
with the understanding of cytokine networks in psoriasis drove to new specific target biologic 
therapies such as anti-IL-23/IL-17. IL-23/Th17 is now recognized as the major axis of the 
psoriatic immune pathway, and antagonists to IL-23 or IL-17 result in the ability to control 
most of the signs and symptoms of clinical disease of patients with psoriasis. 
Thus, psoriasis is considered to be an organ-specific T-cell-driven inflammatory 
disease and T-cells play a dominant pathogenic role in the initiation and maintenance of 
psoriasis. The understanding of the immunopathogenesis of psoriasis is not only important 
because it allows us to identify the key components responsible for inducing and sustaining 
this disease, but it widely enhances our ability to use this information in order to create new 
and more effective treatment options that can significantly attenuate the patients signs and 
symptoms, ultimately improving patients quality of life. 
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